These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Böttinger EP; Jakubczak JL; Haines DC; Bagnall K; Wakefield LM Cancer Res; 1997 Dec; 57(24):5564-70. PubMed ID: 9407968 [TBL] [Abstract][Full Text] [Related]
4. SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors. Tzeng YJ; Zimmermann C; Guhl E; Berg B; Avantaggiati ML; Graessmann A Oncogene; 1998 Apr; 16(16):2103-14. PubMed ID: 9572491 [TBL] [Abstract][Full Text] [Related]
5. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742 [TBL] [Abstract][Full Text] [Related]
6. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus. Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997 [TBL] [Abstract][Full Text] [Related]
7. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Gallahan D; Jhappan C; Robinson G; Hennighausen L; Sharp R; Kordon E; Callahan R; Merlino G; Smith GH Cancer Res; 1996 Apr; 56(8):1775-85. PubMed ID: 8620493 [TBL] [Abstract][Full Text] [Related]
8. An overexpressed N-ras proto-oncogene cooperates with N-methylnitrosourea in mouse mammary carcinogenesis. Mangues R; Kahn JM; Seidman I; Pellicer A Cancer Res; 1994 Dec; 54(24):6395-401. PubMed ID: 7987834 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of the colony-stimulating factor (CSF-1) and/or its receptor c-fms in mammary glands of transgenic mice results in hyperplasia and tumor formation. Kirma N; Luthra R; Jones J; Liu YG; Nair HB; Mandava U; Tekmal RR Cancer Res; 2004 Jun; 64(12):4162-70. PubMed ID: 15205327 [TBL] [Abstract][Full Text] [Related]
10. Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Yang X; Edgerton SM; Kosanke SD; Mason TL; Alvarez KM; Liu N; Chatterton RT; Liu B; Wang Q; Kim A; Murthy S; Thor AD Cancer Res; 2003 May; 63(10):2425-33. PubMed ID: 12750262 [TBL] [Abstract][Full Text] [Related]
11. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Wu Y; Cui K; Miyoshi K; Hennighausen L; Green JE; Setser J; LeRoith D; Yakar S Cancer Res; 2003 Aug; 63(15):4384-8. PubMed ID: 12907608 [TBL] [Abstract][Full Text] [Related]
12. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis. Li M; Lewis B; Capuco AV; Laucirica R; Furth PA Oncogene; 2000 Feb; 19(8):1010-9. PubMed ID: 10713684 [TBL] [Abstract][Full Text] [Related]
14. Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis. Wang XJ; Greenhalgh DA; Jiang A; He D; Zhong L; Medina D; Brinkley BR; Roop DR Oncogene; 1998 Jul; 17(1):35-45. PubMed ID: 9671312 [TBL] [Abstract][Full Text] [Related]
15. Mammary carcinogenesis in transgenic mice expressing a dominant-negative mutant of DNA polymerase beta in their mammary glands. Wang L; Bhattacharyya N; Rabi T; Wang L; Banerjee S Carcinogenesis; 2007 Jun; 28(6):1356-63. PubMed ID: 17166880 [TBL] [Abstract][Full Text] [Related]
16. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Witty JP; Lempka T; Coffey RJ; Matrisian LM Cancer Res; 1995 Apr; 55(7):1401-6. PubMed ID: 7882342 [TBL] [Abstract][Full Text] [Related]
17. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Lin SC; Lee KF; Nikitin AY; Hilsenbeck SG; Cardiff RD; Li A; Kang KW; Frank SA; Lee WH; Lee EY Cancer Res; 2004 May; 64(10):3525-32. PubMed ID: 15150107 [TBL] [Abstract][Full Text] [Related]
18. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Jerry DJ; Kittrell FS; Kuperwasser C; Laucirica R; Dickinson ES; Bonilla PJ; Butel JS; Medina D Oncogene; 2000 Feb; 19(8):1052-8. PubMed ID: 10713689 [TBL] [Abstract][Full Text] [Related]
19. Targeted production of proprotein convertase PC1 enhances mammary development and tumorigenesis in transgenic mice. Blanchard A; Iwasiow B; Yarmill A; Fresnosa A; Silha J; Myal Y; Murphy LC; Chrétien M; Seidah N; Shiu RP Can J Physiol Pharmacol; 2009 Oct; 87(10):831-8. PubMed ID: 20052009 [TBL] [Abstract][Full Text] [Related]
20. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]